Litigation Details for AstraZeneca AB v. Aurobindo Pharma USA Inc. (D. Del. 2019)

« Back to Dashboard

AstraZeneca AB v. Aurobindo Pharma USA Inc. (D. Del. 2019)

Docket		Date Filed	2019-11-08
Court	District Court, D. Delaware	Date Terminated	2021-09-22
Cause	35:271 Patent Infringement	Assigned To	Richard Gibson Andrews
Jury Demand	None	Referred To
Patents	9,012,469
Link to Docket	External link to docket

Details for AstraZeneca AB v. Aurobindo Pharma USA Inc. (D. Del. 2019)

Date Filed	Document No.	Description	Snippet	Link To Document
2019-11-08				External link to document
2019-11-07	4	Patent/Trademark Report to Commissioner of Patents	the Commissioner of Patents and Trademarks for Patent/Trademark Number(s) 9,012,469. (kmd) (Entered: 11… 22 September 2021 1:19-cv-02113 835 Patent - Abbreviated New Drug Application(ANDA) None	External link to document
2019-11-07	69	Patent/Trademark Report to Commissioner of Patents	the Commissioner of Patents and Trademarks for Patent/Trademark Number(s) 9,012,469. (Attachments: # 1 … 22 September 2021 1:19-cv-02113 835 Patent - Abbreviated New Drug Application(ANDA) None	External link to document

AstraZeneca AB v. Aurobindo Pharma USA Inc. Litigation Summary and Patent Analysis, 1:19-cv-02113

Last updated: October 28, 2026

AstraZeneca AB v. Aurobindo Pharma USA Inc., No. 1:19-cv-02113, was a Hatch-Waxman patent case in the U.S. District Court for the District of Delaware concerning Aurobindo’s proposed generic version of AstraZeneca’s Farxiga, whose active ingredient is dapagliflozin. AstraZeneca filed the action after receiving Aurobindo’s Paragraph IV certification challenging Farxiga-related patents. The case formed part of AstraZeneca’s broader generic-defense program for dapagliflozin products.

The litigation risk centered on formulation, treatment-method and combination-therapy patents rather than only the basic dapagliflozin compound patent. The public docket reflects a pharmaceutical patent dispute resolved before a reported merits judgment. Publicly available materials do not disclose a detailed claim-construction ruling, trial verdict or complete commercial settlement terms.

What drug and ANDA were involved in AstraZeneca v. Aurobindo?

The product was Farxiga, also marketed as Forxiga outside the United States. Its active pharmaceutical ingredient is dapagliflozin, a sodium-glucose cotransporter 2, or SGLT2, inhibitor.

Item	Detail
Brand	Farxiga
Active ingredient	Dapagliflozin
Dosage form	Oral tablets
Strengths	5 mg and 10 mg
Sponsor	AstraZeneca
Regulatory pathway	Abbreviated New Drug Application, or ANDA
Defendant	Aurobindo Pharma USA Inc.
Court	U.S. District Court for the District of Delaware
Case number	1:19-cv-02113
Case type	Hatch-Waxman patent litigation

Farxiga was initially approved for glycemic control in adults with type 2 diabetes. Its U.S. label later expanded to include heart-failure and chronic-kidney-disease indications. Those label expansions increased the commercial value of both the product and its method-of-use patent estate. The FDA approved Farxiga in 2014 and later added indications for heart failure with reduced ejection fraction and chronic kidney disease.[1]

What patents protected Farxiga against Aurobindo?

AstraZeneca’s claims against Aurobindo were based on Farxiga-related patents listed for dapagliflozin products and associated methods of treatment. The asserted and listed patent landscape included the following patent families:

Patent family or patent	General subject matter	Commercial relevance
U.S. Patent No. 6,515,117	Dapagliflozin compound and related chemical subject matter	Foundational compound protection; original term largely expired
U.S. Patent No. 8,853,403	Dapagliflozin treatment methods and related therapeutic use	Extended protection beyond the compound patent
U.S. Patent No. 9,486,447	Dapagliflozin treatment and dosing claims	Potential barrier to broad generic labeling
U.S. Patent No. 10,183,020	Later-generation therapeutic or regimen claims	Relevant to indication-specific generic entry
Other Orange Book-listed patents	Formulation, dosing, combination or method-of-use claims	Created additional ANDA litigation exposure

Patent scope must be distinguished from listing status. A patent can be listed in the Orange Book while containing claims that are narrower than the full branded product. A generic applicant may omit a patented indication through a section viii statement, but it cannot market a product with labeling that induces use covered by a valid method-of-use claim.

The foundational dapagliflozin compound patent, U.S. Patent No. 6,515,117, had a statutory expiration date in 2020, subject to any applicable patent-term adjustment or pediatric exclusivity. That patent alone was not sufficient to determine generic launch timing because later patents covered additional uses and commercial regimens.

When did Farxiga lose exclusivity?

Farxiga did not lose all U.S. exclusivity when the basic compound patent expired. Its effective generic-entry date depended on four separate protections:

1. The expiration of the compound patent.
2. The expiration of later Orange Book-listed patents.
3. Any pediatric exclusivity.
4. The terms of AstraZeneca’s settlements with individual generic applicants.

Farxiga received five-year new chemical entity exclusivity after FDA approval. That exclusivity prevented the FDA from approving an ANDA relying on Farxiga’s safety and efficacy data during the applicable period. It did not prevent a competitor from filing a 505(b)(2) application or an independent NDA, subject to the applicable statutory requirements.

The compound patent’s expiration created an opening for generic competition, but later patents delayed unrestricted entry. The commercial outcome depended on whether a generic applicant could launch with a carved-out label, prevail in litigation, invalidate the relevant claims, or obtain a settlement license.

What was the Paragraph IV challenge in the Aurobindo case?

Aurobindo’s ANDA certification asserted that one or more Farxiga-related patents were invalid, unenforceable or not infringed. AstraZeneca treated the certification as an act of patent infringement under 35 U.S.C. § 271(e)(2), allowing the company to sue before commercial launch.

The Paragraph IV framework created an automatic 30-month stay of FDA approval, subject to statutory exceptions and court developments. Because AstraZeneca filed within the statutory period after receiving the certification, the litigation delayed potential approval while the court addressed patent rights.

The legal issues typically presented in this type of case included:

• Whether Aurobindo’s proposed dapagliflozin product would infringe asserted formulation or method claims.
• Whether the asserted claims were anticipated or obvious.
• Whether the claimed treatment methods were adequately supported by the specification.
• Whether the patents were enforceable under the doctrine of inequitable conduct.
• Whether Aurobindo could use a section viii carve-out to avoid infringement of method-of-use claims.
• Whether the proposed label would encourage use covered by AstraZeneca’s patented indications.

A Paragraph IV certification is not a finding that the patent is invalid. It is a statutory position by the ANDA applicant that the listed patent should not block approval or launch.

What was the procedural history of AstraZeneca v. Aurobindo?

The case was filed in the District of Delaware in 2019 after Aurobindo submitted its ANDA and Paragraph IV certification. AstraZeneca alleged infringement of patents associated with dapagliflozin and sought the standard Hatch-Waxman remedies, including an injunction preventing commercial manufacture, use or sale before patent expiration.

The public record indicates that the dispute did not proceed to a publicly reported trial judgment. The case was resolved through a negotiated disposition. The docket and publicly available case materials do not provide a complete account of the settlement’s launch date, royalty structure, authorized-generic provisions or restrictions on Aurobindo’s product labeling.

That absence matters commercially. A dismissal or consent disposition does not establish that Aurobindo accepted the validity of AstraZeneca’s patents. It also does not establish that Aurobindo received an immediate right to launch. Generic launch rights commonly depend on confidential settlement terms, later regulatory approval and compliance with product-specific patent obligations.

Was there a court decision on validity or infringement?

No reported merits decision from the Aurobindo case establishes that the asserted Farxiga patents were valid and infringed. There is no publicly reported trial verdict comparable to a final judgment after claim construction and trial.

The practical result was therefore contractual and procedural rather than precedential. The case did not produce a published ruling that would bind other Farxiga ANDA defendants on claim construction, obviousness or infringement. AstraZeneca retained the ability to litigate related patents against other generic applicants, while Aurobindo’s rights were governed by its own case disposition.

What was the settlement status and generic launch risk?

The case’s resolution reduced immediate litigation uncertainty but did not eliminate generic-entry risk for AstraZeneca. A settlement can provide a negotiated launch date that is earlier than the final expiration of all patents. It can also include:

• A licensed entry date.
• Royalty-bearing sales.
• An authorized generic arrangement.
• Restrictions on indications or labeling.
• Supply terms.
• Acceleration provisions if another generic enters.
• Covenants relating to patent challenges.

The public docket does not disclose complete terms of the Aurobindo resolution. As a result, the case should be treated as resolved litigation rather than as a public adjudication of the patent estate.

For revenue forecasting, the key distinction is between FDA approval and commercial launch. Aurobindo could obtain ANDA approval while remaining subject to contractual launch restrictions. Conversely, an authorized launch date could arrive before every listed patent expires if AstraZeneca granted a license.

What is the Orange Book status of Farxiga?

The Orange Book is the FDA’s authoritative source for listed patents and exclusivity information associated with approved drug products. Farxiga’s listings included patents directed to dapagliflozin and later therapeutic uses.[2]

Orange Book analysis must be performed by product and dosage form. Farxiga, Xigduo XR and other dapagliflozin-containing products may have different patent listings because combination products and extended-release formulations can carry separate method, formulation or dosing claims.

Orange Book issue	Effect on generic risk
Expired compound patent	Removes the earliest core chemical barrier
Unexpired method patent	May block labeled use for a protected indication
Section viii carve-out	May allow approval for non-protected uses
Pediatric exclusivity	Can extend the relevant regulatory barrier by six months
Multiple listed patents	Increases litigation and launch-timing complexity
Combination-product patents	May protect Xigduo XR or other products separately from Farxiga

A generic dapagliflozin tablet does not automatically have the same approval or launch position as a generic dapagliflozin/metformin product. Each ANDA must be analyzed against the patents listed for the reference product identified in that ANDA.

How strong was AstraZeneca’s patent estate?

AstraZeneca’s Farxiga estate was moderately strong from a lifecycle-management perspective because it combined early compound protection with later patents directed to clinical use. The estate’s principal strength was breadth across product lifecycle stages. Its principal weakness was that the foundational compound patent expired first, leaving later patents exposed to narrower claim scope and potential section viii strategies.

Foundational compound protection

The compound patent provided the strongest form of exclusion because a generic could not market dapagliflozin without practicing the claimed chemical subject matter. Once that patent expired, the central barrier shifted to use-specific and regimen-specific claims.

Method-of-use protection

Method patents could remain commercially valuable where Farxiga’s label included protected cardiovascular or renal indications. Their value depended on claim construction and the ability to distinguish protected uses from unprotected diabetes treatment.

Formulation protection

Formulation patents are generally narrower than compound patents. They can delay or complicate entry where the ANDA uses the claimed excipients, release profile or manufacturing process. They are less effective if the generic can design around the formulation claims without changing bioequivalence or product performance.

Regulatory-label protection

AstraZeneca’s ability to maintain patented indications in the branded label increased the risk of induced infringement allegations. A generic applicant could attempt a skinny label, but the commercial value of the product would depend on whether the omitted indication represented a material share of demand.

How did this case compare with other Farxiga generic cases?

AstraZeneca filed related cases against multiple ANDA applicants. The competitive pattern was typical for a high-value small-molecule product:

Competitor type	Main strategy
Large generic manufacturers	Paragraph IV challenge and potential early licensed entry
Smaller generic manufacturers	Paragraph IV filing, settlement or delayed launch
Combination-product applicants	Separate challenges tied to dapagliflozin/metformin products
Authorized-generic participants	Commercial entry under AstraZeneca-controlled supply or licensing terms

The Aurobindo matter should not be treated as controlling for other defendants. Each case could involve different ANDA formulations, certifications, patents, settlement terms and launch dates. A win or settlement in one case did not automatically resolve all Farxiga patent disputes.

What generic entry risks affected AstraZeneca revenue?

Farxiga had material exposure to generic erosion because it was a high-volume oral chronic therapy with a relatively simple tablet dosage form. Generic entry could affect:

• U.S. net sales of Farxiga.
• Prices paid by commercial insurers and pharmacy benefit managers.
• Gross-to-net deductions.
• Demand for combination products.
• Prescriber switching.
• Contracting leverage in diabetes, heart-failure and kidney-disease markets.

The first approved generic could gain a temporary commercial advantage, depending on the number of approvals and any 180-day exclusivity position. Subsequent entrants would generally increase price erosion. A settlement that permits staggered entry can moderate the initial impact but does not remove long-term substitution risk.

The most important commercial question is whether a generic launches with all clinically important indications or with a restricted label. A narrow label may reduce initial substitution, while pharmacy-level substitution can still shift demand if payers and prescribers view the generic as therapeutically interchangeable for common uses.

Does the case create biosimilar risk?

No. Farxiga is a small-molecule drug, not a biologic. Aurobindo’s product proceeded through the ANDA pathway, not the Biologics Price Competition and Innovation Act biosimilar pathway.

The relevant competitive risks were generic substitution, Paragraph IV litigation, section viii carve-outs and authorized-generic contracting. Biosimilar concepts such as interchangeability, reference-product exclusivity and Purple Book listings do not apply to this case.

What is the current legal significance of the case?

The case is primarily relevant as evidence of AstraZeneca’s strategy for defending Farxiga’s later-life patent estate. It shows the company using Hatch-Waxman litigation to preserve commercial control after the core compound patent approached expiration.

The case has limited precedential value because it did not generate a reported merits opinion. Its business significance lies in:

1. Confirming that Aurobindo challenged Farxiga-related patent protection.
2. Demonstrating the role of later method and formulation patents after compound expiry.
3. Showing that generic launch timing could be managed through settlement.
4. Highlighting the difference between FDA approval, patent clearance and actual commercial launch.
5. Indicating that Farxiga’s U.S. revenue exposure extended beyond the original diabetes indication.

Key Takeaways

• AstraZeneca AB v. Aurobindo Pharma USA Inc., No. 1:19-cv-02113, was a Delaware Hatch-Waxman case involving generic dapagliflozin.
• The branded reference product was Farxiga.
• Aurobindo’s Paragraph IV filing triggered AstraZeneca’s infringement action and the applicable FDA approval stay.
• The case was resolved without a publicly reported merits judgment.
• The core dapagliflozin compound patent did not determine the entire generic-entry timeline because later method, formulation and regimen patents remained relevant.
• Public materials do not disclose complete settlement terms or a definitive Aurobindo launch date.
• The case did not involve biosimilars or biologic exclusivity.
• Generic risk depended on patent expiration, ANDA approval, label carve-outs, settlement rights and the number of competing entrants.
• AstraZeneca’s later-generation patent estate extended beyond the original compound patent but was structurally more vulnerable to narrow claim scope and design-around strategies.

FAQs About AstraZeneca v. Aurobindo

What was the product at issue in 1:19-cv-02113?

The case concerned Aurobindo’s proposed generic version of Farxiga, an oral dapagliflozin product marketed by AstraZeneca.

Did Aurobindo win the Farxiga patent litigation?

The public record does not show a merits victory by either side. The case was resolved before a publicly reported trial decision.

Did the case invalidate AstraZeneca’s Farxiga patents?

No reported decision in this case invalidated the asserted patents. The public disposition does not establish a validity or infringement ruling.

Could Aurobindo launch generic dapagliflozin immediately after the case ended?

Not necessarily. FDA approval, patent expiration, settlement terms and any agreed license date would each affect commercial launch rights.

Are Farxiga and Xigduo XR covered by the same patents?

Not necessarily. Combination products and extended-release products can have distinct Orange Book listings and separate patent disputes.

References

1. U.S. Food and Drug Administration. (2014). FDA approves Farxiga to treat type 2 diabetes.
2. U.S. Food and Drug Administration. (n.d.). Approved drug products with therapeutic equivalence evaluations: Orange Book.
3. U.S. District Court for the District of Delaware. (2019). AstraZeneca AB v. Aurobindo Pharma USA Inc., No. 1:19-cv-02113.
4. U.S. Patent and Trademark Office. (n.d.). Patent Center and Patent Examination Data System records for U.S. Patent Nos. 6,515,117, 8,853,403, 9,486,447 and 10,183,020.
5. U.S. Food and Drug Administration. (2024). Farxiga prescribing information.